Upstream Bio announces verekitug met the primary endpoint

Upstream Bio (UPB) presented additional data from the Phase 2 Vibrant clinical trial evaluating verekitug in participants with chronic rhinosinusitis with nasal polyps. The additional analyses incorporated a worst-observation carried-forward, WOCF, statistical approach to adjust for concomitant rescue therapy use, including nasal polyp surgery, systemic corticosteroids, or escalation of background treatments. The data support previously reported positive top-line results and were presented in a late-breaking poster session at the American Academy of Allergy Asthma & Immunology, AAAAI, 2026 Annual Meeting in Philadelphia. Dosed 100 mg every 12 weeks, verekitug met the study’s primary endpoint using both the WOCF and primary analyses, demonstrating an improved placebo-adjusted reduction in NPS of -1.95 in the WOCF analysis as compared to a reduction of -1.77 in the primary analysis at week 24. The trial also showed a placebo-adjusted reduction in the patient-reported NCS, a key secondary endpoint, of -0.96 in the WOCF analysis as compared to -0.77 in the primary analysis.